The Kinetics of SARS-CoV-2 Antibody Development Is Associated with Clearance of RNAemia
暂无分享,去创建一个
D. Lauffenburger | N. Hacohen | M. Sade-Feldman | G. Alter | M. Filbin | K. Kays | M. Gentili | M. Goldberg | Chuangqi Wang | S. Fischinger | Yijia Li | K. Bowman | J. Regan | J. P. Flynn | P. Kaplonek | Jonathan Z Li | Jonathan Z. Li | Kyle R. Kays | Moshe Sade-Feldman
[1] A. Casadevall,et al. Early Outpatient Treatment for Covid-19 with Convalescent Plasma , 2022, The New England journal of medicine.
[2] M. Landray,et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial , 2021, medRxiv.
[3] Peng Wang,et al. B.1.1.529 escapes the majority of SARS-CoV-2 neutralizing antibodies of diverse epitopes , 2021 .
[4] S. Hoehl,et al. Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and monoclonal antibodies , 2021, medRxiv.
[5] Megan Cully. A tale of two antiviral targets — and the COVID-19 drugs that bind them , 2021, Nature Reviews Drug Discovery.
[6] Junhua Pan,et al. Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain , 2021, Science.
[7] J. Dillner,et al. Duration of SARS-CoV-2 viremia and its correlation to mortality and inflammatory parameters in patients hospitalized for COVID-19: a cohort study , 2021, Diagnostic Microbiology and Infectious Disease.
[8] Peter J. Richardson,et al. Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. , 2021, JAMA.
[9] R. Baric,et al. Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy , 2021, Nature.
[10] Kelly A. Fusco,et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial , 2021, Nature Medicine.
[11] J. Mascola,et al. A Monoclonal Antibody for Malaria Prevention. , 2021, The New England journal of medicine.
[12] Simon C Watkins,et al. SARS-CoV-2 Viremia is Associated with COVID-19 Severity and Predicts Clinical Outcomes. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] L. Stamatatos,et al. Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy , 2021, Immunity.
[14] M. C. Muenker,et al. Delayed production of neutralizing antibodies correlates with fatal COVID-19 , 2021, Nature Medicine.
[15] Paul J. Hoover,et al. Longitudinal proteomic analysis of severe COVID-19 reveals survival-associated signatures, tissue-specific cell death, and cell-cell interactions , 2021, Cell Reports Medicine.
[16] N. Hacohen,et al. Trajectories of Pulmonary Epithelial and Endothelial Injury Markers in COVID-19 Patients Requiring Respiratory Support at Presentation , 2021, A13. A013 ARDS IN THE TIME OF COVID-19.
[17] S. Richardson,et al. Targeting Fc effector function in vaccine design , 2021, Expert opinion on therapeutic targets.
[18] J. Richards,et al. Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality , 2021, medRxiv.
[19] M. Diamond,et al. Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein , 2021, Cell.
[20] M. Landray,et al. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial , 2021, medRxiv.
[21] N. Hacohen,et al. SARS-CoV-2 Viremia is Associated with Distinct Proteomic Pathways and Predicts COVID-19 Outcomes , 2021, medRxiv.
[22] D. Lauffenburger,et al. Comorbid illnesses are associated with altered adaptive immune responses to SARS-CoV-2 , 2021, JCI insight.
[23] Michele D. Sobolewski,et al. Intractable Coronavirus Disease 2019 (COVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication in a Chimeric Antigen Receptor-Modified T-Cell Therapy Recipient: A Case Study , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[24] A. Sette,et al. Adaptive immunity to SARS-CoV-2 and COVID-19 , 2021, Cell.
[25] in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, , 2021 .
[26] Samuel M. Brown,et al. A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19 , 2020, The New England Journal of Medicine.
[27] John D. Davis,et al. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 , 2020, The New England journal of medicine.
[28] Gaurav D. Gaiha,et al. Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host , 2020, The New England journal of medicine.
[29] Matthew S. Miller,et al. Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike , 2020, Cell Reports Medicine.
[30] D. Lauffenburger,et al. Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality , 2020, Cell.
[31] J. Dillner,et al. SARS-CoV-2 RNA in serum as predictor of severe outcome in COVID-19: a retrospective cohort study. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[32] Kelsey K. Finn,et al. Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19 , 2020, Cell.
[33] Kira L. Newman,et al. Distinct Early Serological Signatures Track with SARS-CoV-2 Survival , 2020, Immunity.
[34] Michael D Healy,et al. SARS-CoV-2 viral load is associated with increased disease severity and mortality , 2020, Nature Communications.
[35] Dong Men,et al. Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients , 2020, medRxiv.
[36] Michael Proschan,et al. A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. , 2019, The New England journal of medicine.
[37] G. Alter,et al. A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation☆ , 2019, Journal of immunological methods.
[38] N. Olchanski,et al. Palivizumab Prophylaxis for Respiratory Syncytial Virus: Examining the Evidence Around Value , 2018, Open forum infectious diseases.
[39] Xiliang Wang,et al. Kinetics of pulmonary immune cells, antibody responses and their correlations with the viral clearance of influenza A fatal infection in mice , 2014, Virology Journal.
[40] Douglas A. Lauffenburger,et al. In Vivo Systems Analysis Identifies Spatial and Temporal Aspects of the Modulation of TNF-α–Induced Apoptosis and Proliferation by MAPKs , 2011, Science Signaling.